Skip to Content

Padcev (enfortumab vedotin) Disease Interactions

There are 3 disease interactions with Padcev (enfortumab vedotin):

Major

Enfortumab vedotin (applies to Padcev) hepatic impairment

Major Potential Hazard, Moderate plausibility. Applicable conditions: Liver Disease

Avoid the use of enfortumab vedotin in patients with moderate or severe hepatic impairment as it has not been studied in these patients. No adjustment in the starting dose is required when treating patients with mild hepatic impairment.

Moderate

Enfortumab vedotin (applies to Padcev) hyperglycemia/diabetes

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Diabetes Mellitus

Hyperglycemia occurred in patients treated with enfortumab vedotin, including death, and diabetic ketoacidosis (DKA) in those with and without preexisting-existing diabetes mellitus. The incidence of Grade 3-4 hyperglycemia increased consistently in patients with higher body mass index and in patients with higher baseline A1C. Closely monitor blood glucose levels in patients with, or at risk for, diabetes mellitus or hyperglycemia. If blood glucose is elevated (>250 mg/dL), withhold treatment.

Moderate

Enfortumab vedotin (applies to Padcev) peripheral neuropathy

Moderate Potential Hazard, Moderate plausibility.

Peripheral neuropathy, predominantly sensory, occurred in 49% of the patients treated with enfortumab vedotin in clinical trials. Peripheral neuropathy occurred in patients with or without preexisting peripheral neuropathy. Monitor patients for symptoms of new or worsening peripheral neuropathy and consider dose interruption or dose reduction when peripheral neuropathy occurs. Permanently discontinue treatment in patients that develop Grade >3 peripheral neuropathy.

Padcev (enfortumab vedotin) drug interactions

There are 288 drug interactions with Padcev (enfortumab vedotin)

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.